Potential Alzheimer’s Vaccine Undergoing Pre-Clinical Trial Tests

Potential Alzheimer’s Vaccine Undergoing Pre-Clinical Trial Tests
Scientists have developed a novel form of vaccine targeting the two main proteins triggering Alzheimer's disease, amyloid-beta and tau protein. Researchers and physicians have seen an increase in Alzheimer's disease, with more than 7.5 million new cases diagnosed worldwide per year. There is an urgent but still unmet need for a vaccine and effective treatment for dementia, one of the most detrimental features of Alzheimer's disease. Researchers at Flinders University in Australia, collaborating with colleagues at the Institute of Molecular Medicine (IMM) and the University of California at Irvine (UCI), have designed a successful vaccine formulation that targets the abnormal beta-amyloid and
Subscribe or to access all post and page content.